Pharmacological ascorbate (P-AscH-), as an adjuvant to standard treatment for glioblastoma, may selectively enhance cancer cell killing. The mechanisms of P-AscH- have been associated with redox changes in the labile iron pool. This study applies T2* and QSM to assess the redox changes in 40 glioblastoma patients receiving standard treatment and adjuvant P-AscH-. The results demonstrate an increase in T2* values and a decrease in QSM values within contrast-enhancing lesions 1 hour after P-AscH- infusion. These changes in T2* and QSM may result from the redox changes by P-AscH-, supporting the potential for imaging assessment of response to P-AscH-.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords